Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950973 | 1.00 | ERN1 (0.43) | ERN1CYP3A4MAPTTRPA1ATM | |
| SCHEMBL8736584 | 0.86 | ERN1 (0.47) | ERN1CYP3A4MAPTTRPA1ATM | |
| SCHEMBL31351301 | 0.84 | ERN1 (0.49) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL7717189 | 0.84 | ERN1 (0.49) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL3312483 | 0.82 | ERN1 (0.47) | ERN1CYP3A4MAPTTRPA1ATM | |
| SCHEMBL4650198 | 0.82 | CYP3A4 (0.44) | ERN1CYP3A4MAPTTRPA1KDM4E | |
| SCHEMBL1311843 | 0.80 | ALDH1A1 (0.39) | ERN1CYP3A4MAPTKDM4ETDP1 | |
| SCHEMBL24677699 | 0.78 | ERN1 (0.46) | ERN1CYP3A4MAPTESR1ESR2 | |
| SCHEMBL7864192 | 0.78 | ERN1 (0.50) | ERN1CYP3A4MAPTESR1ESR2 | |
| SCHEMBL30134282 | 0.78 | ERN1 (0.46) | ERN1CYP3A4MAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | claimed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | claimed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | claimed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11479569-B2 | Compound, photopolymerization initiator, photocurable composition and cured product thereof, and photocurable ink and print using the same | DIC CORPORATION (JP) | 2022-10-25 | — | — | US | disclosed |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-10-13 | — | — | US | disclosed |
| US-20200270286-A1 | COMPOUND, PHOTOPOLYMERIZATION INITIATOR, PHOTOCURABLE COMPOSITION AND CURED PRODUCT THEREOF, AND PHOTOCURABLE INK AND PRINT USING THE SAME | DIC CORPORATION (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2056780-A1 | REDUCTIVE COLOUR REMOVAL | Henkel AG & Co. KGaA (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008055756-A1 | REDUCTIVE COLOUR REMOVAL | HENKEL AG & CO. KGAA (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-0797575-B1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| US-5959113-A | REACTING A DIKETONE DERIVATIVE WITH AN ALDEHYDE DERIVATIVE; ADMINISTERING TO TREAT ATHEROSCLEROSIS, PSORIASIS, ALOPECIA AND TUMORS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0797575-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018626-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270286-A1 | COMPOUND, PHOTOPOLYMERIZATION INITIATOR, PHOTOCURABLE COMPOSITION AND CURED PRODUCT THEREOF, AND PHOTOCURABLE INK AND PRINT USING THE SAME | TYR, CRY1, CCNA1 | ERN1 936/4885CYP3A4 1807/4885MAPT 2427/4885 |
| US-11479569-B2 | Compound, photopolymerization initiator, photocurable composition and cured product thereof, and photocurable ink and print using the same | TYR, CRY1, CCNA1 | ERN1 936/4885CYP3A4 1807/4885MAPT 2427/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | UGT1A1, CYP3A5, CYP3A7 | ERN1 2225/4885CYP3A4 4/4885MAPT 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.